Featured Research

from universities, journals, and other organizations

Northwestern Is Testing Experimental Therapies For Crohn's Disease

Date:
August 9, 2002
Source:
Northwestern University
Summary:
Researchers at the Inflammatory Bowel Disease Center at Northwestern University are conducting clinical trials of several innovative approaches to the treatment of Crohn's disease, including experimental drugs and a new swallowable video camera that produces high-quality images of the small intestine.

CHICAGO --- Researchers at the Inflammatory Bowel Disease Center at Northwestern University are conducting clinical trials of several innovative approaches to the treatment of Crohn's disease, including experimental drugs and a new swallowable video camera that produces high-quality images of the small intestine.

Research related to these Crohn's disease studies appears in the Aug. 8 issue of The New England Journal of Medine.

In addition to aiding diagnosis by affording a more complete view of the small intestine without pain or discomfort to the patient, the "camera-in-a-capsule" enables physicians to direct appropriate treatment and determine the effect of new medications for Crohn's disease.

The studies are headed by Alan Buchman, M.D., associate professor of medicine at The Feinberg School of Medicine and director of the Inflammatory Bowel Disease Center at Northwestern.

Crohn's is a serious inflammatory disease of the gastrointestinal tract that causes diarrhea, abdominal cramps, fever and rectal bleeding. The cause of Crohn's disease is unknown.

Among the experimental medications for Crohn's disease undergoing investigation at Northwestern is a synthetic, oral form of interleukin-11, a chemical produced by white blood cells in response to inflammation. This study of interleukin-11 for Crohn's disease is the first to be conducted in humans.

Research has shown that interleukin-11 is both an anti-inflammatory agent and a potent growth factor that aids in the healing process. Other drugs used to treat Crohn's disease, such as prednisone, only reduce inflammation.

In a separate study, Northwestern also is assessing the use of interleukin-11 in ulcerative colitis.

Northwestern will be studying two experimental drugs for Crohn's disease that prevent inflammation by blocking the process by which white blood cells adhere to areas of inflammation in the bowel.

Another investigational study for Crohn's disease will focus on a drug that blocks production of an inflammation-causing chemical known as tumor necrosis factor.

For information on these and other studies for the treatment of Crohn's disease and ulcerative colitis, contact the Northwestern Inflammatory Bowel Disease Center at (312) 695-4IBD (or 4423).


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "Northwestern Is Testing Experimental Therapies For Crohn's Disease." ScienceDaily. ScienceDaily, 9 August 2002. <www.sciencedaily.com/releases/2002/08/020808075546.htm>.
Northwestern University. (2002, August 9). Northwestern Is Testing Experimental Therapies For Crohn's Disease. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2002/08/020808075546.htm
Northwestern University. "Northwestern Is Testing Experimental Therapies For Crohn's Disease." ScienceDaily. www.sciencedaily.com/releases/2002/08/020808075546.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins